Efficacy and safety of low‐dose atorvastatin plus ezetimibe for primary hypercholesterolemia: A randomized, double‐blind, multicenter phase 3 trial
Lipids · 2025
DOI: 10.1002/lipd.12442 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Lipids, 2025. Verfasst von Tae Oh Kim und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. Hauptthemen laut MEDLINE: Hypercholesterolemia, Anticholesteremic Agents, Azetidines, Heptanoic Acids. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chong Kun Dang Pharmaceutical Corp.
Abstract (Originalsprache)
Studies have suggested that low‐dose statin monotherapy may be insufficient for target LDL‐C levels. In this randomized, double‐blind, multicenter phase 3 trial, we evaluated the efficacy of combined ezetimibe and low‐dose atorvastatin in 222 Korean patients with primary hypercholesterolemia. Participants received either 10‐mg ezetimibe/5‐mg atorvastatin (EZE10/ATV5), 10‐mg ezetimibe (EZE10), 5‐mg atorvastatin (ATV5), or 10‐mg atorvastatin (ATV10). At 8 weeks, EZE10/ATV5 achieved the greatest LDL‐C reduction (−44.8%) compared with EZE10 (−12.7%, p < 0.0001), ATV5 (−27.3%, p < 0.0001), and ATV10 (−32.0%, p = 0.0012). The combination therapy showed the highest LDL‐C goal achievement rate (41.1% vs. EZE10 8.9%, p < 0.0001; ATV5 10.9%, p < 0.0001; ATV10 27.3%, p = 0.0342), particularly in moderate to high‐risk patients. Additionally, EZE10/ATV5 had the lowest adverse events among all groups (6.9% vs. 15.0%, 12.3%, and 27.6%, p = 0.017), with most events being mild. These findings suggest that the combination of ezetimibe and low‐dose atorvastatin provides superior lipid‐lowering efficacy with an improved safety profile, offering an effective treatment for primary hypercholesterolemia in Korean patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
- Department of Cardiology, Gil Medical Center, Gachon University of Medicine and Science, Incheon, Republic of Korea.
- Department of Cardiology, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea.
- Department of Cardiology, Dongsan Hospital, Keimyung University College of Medicine, Daegu, Republic of Korea.
- Division of Cardiology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Republic of Korea.
- Division of Cardiology, Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea.
ORCID-Profile: Tae Oh Kim
Förderung
- Chong Kun Dang Pharmaceutical Corp
Zitieren
APA
Kim, T. O., Lee, K., Cho, J. M., Yoon, H. J., Park, T. H., Choi, J. H., Suh, J. W., Kim, S. Y., Lim, H. S., Park, J. S., Cho, D. K., Park, G. M., Ahn, S. G., Shin, S., Kwon, S. U., Kim, D. H., Lee, S. R., Sung, J. H., Park, H. C., & Lee, S. W. (2025). Efficacy and safety of low‐dose atorvastatin plus ezetimibe for primary hypercholesterolemia: A randomized, double‐blind, multicenter phase 3 trial. Lipids. https://doi.org/10.1002/lipd.12442
Vancouver
Kim TO, Lee K, Cho JM, Yoon HJ, Park TH, Choi JH, et al. Efficacy and safety of low‐dose atorvastatin plus ezetimibe for primary hypercholesterolemia: A randomized, double‐blind, multicenter phase 3 trial. Lipids. 2025. doi:10.1002/lipd.12442
BibTeX
@article{Kim2025,
author = {Kim, Tae Oh and Lee, Kyounghoon and Cho, Jin-Man and Yoon, Hyuck-Jun and Park, Tae-Ho and Choi, Jung Hyun and Suh, Jung-Won and Kim, Seok-Yeon and Lim, Hong-Seok and Park, Jong-Seon and Cho, Deok-Kyu and Park, Gyung-Min and Ahn, Sung-Gyun and Shin, Sanghoon and Kwon, Sung Uk and Kim, Dae-Hyeok and Lee, Sang-Rok and Sung, Jung-Hoon and Park, Hwan-Cheol and Lee, Seung-Whan},
title = {Efficacy and safety of low‐dose atorvastatin plus ezetimibe for primary hypercholesterolemia: A randomized, double‐blind, multicenter phase 3 trial},
journal = {Lipids},
year = {2025},
doi = {10.1002/lipd.12442}
}
EUVIMED